| |
| |
|
| Insider
Information: |
Oren Dan |
| Relationship: |
10% Owner |
| City: |
Or Akiva |
| State: |
L3 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
106,486,757 |
|
|
Indirect Shares
|
185,591,533 |
|
|
| Direct
Value |
$1,150,819,206 |
|
|
|
Indirect Value
|
$1,568,026,841 |
|
|
| Total
Shares |
292,078,290 |
|
|
| Total
Value |
$2,718,846,047 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
3
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
3.0
|
0.0
|
| Percentage
Gain/Loss : |
 135.5%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Tekmira Pharmaceuticals Corp |
TKMR |
10% Owner |
|
0 |
2016-07-08 |
16,013,540 |
Premium* |
|
|
Sio Gene Therapies Inc |
SIOX |
10% Owner |
|
0 |
2019-03-18 |
105,952,381 |
Premium* |
|
|
Myovant Sciences Ltd. |
MYOV |
10% Owner |
|
0 |
2019-06-04 |
40,765,599 |
Premium* |
|
|
Urovant Sciences Ltd. |
UROV |
10% Owner |
2018-10-01 |
0 |
2019-06-19 |
22,860,013 |
Premium* |
|
|
Protalix Biotherapeutics |
PLX |
10% Owner |
2021-06-03 |
3,637,314 |
|
0 |
Premium* |
|
|
Roivant Sciences Ltd. |
ROIV |
10% Owner |
2022-11-10 |
102,849,443 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
44 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TKMR |
Tekmira Pharmaceuticals C... |
10% Owner |
– – • |
2015-03-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
16,013,540 |
|
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2015-06-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
75,000,000 |
|
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2016-07-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
75,000,000 |
|
- |
|
| TKMR |
Tekmira Pharmaceuticals C... |
10% Owner |
– – • |
2016-07-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
16,013,540 |
|
- |
|
| MYOV |
Myovant Sciences Ltd. |
10% Owner |
– – • |
2016-10-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
37,231,342 |
|
- |
|
| PLX |
Protalix Biotherapeutics |
10% Owner |
– – • |
2021-02-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,556,031 |
|
- |
|
| ROIV |
Roivant Sciences Ltd. |
10% Owner |
– – • |
2021-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
98,809,158 |
|
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2018-12-18 |
4 |
B |
$1.00 |
$10,000,000 |
I/I |
10,000,000 |
99,285,714 |
1.5 |
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2019-03-18 |
4 |
B |
$1.50 |
$10,000,001 |
I/I |
6,666,667 |
105,952,381 |
1.5 |
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2018-06-05 |
4 |
B |
$1.75 |
$25,000,000 |
I/I |
14,285,714 |
89,285,714 |
1.5 |
- |
|
| PLX |
Protalix Biotherapeutics |
10% Owner |
– – • |
2021-06-03 |
4 |
S |
$2.25 |
$1,932,304 |
D/D |
(857,506) |
3,637,314 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
10% Owner |
– – • |
2021-06-02 |
4 |
S |
$2.56 |
$156,553 |
D/D |
(61,211) |
4,494,820 |
0 |
- |
|
| ROIV |
Roivant Sciences Ltd. |
10% Owner |
– – • |
2022-04-22 |
4 |
B |
$3.83 |
$121,319 |
D/D |
31,685 |
98,840,843 |
2.45 |
% |
|
| ROIV |
Roivant Sciences Ltd. |
10% Owner |
– – • |
2022-04-25 |
4 |
B |
$3.91 |
$33,635 |
D/D |
8,600 |
98,849,443 |
2.37 |
% |
|
| ROIV |
Roivant Sciences Ltd. |
10% Owner |
– – • |
2022-11-10 |
4 |
B |
$5.00 |
$20,000,000 |
D/D |
4,000,000 |
102,849,443 |
2.45 |
% |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-05-16 |
4 |
AB |
$6.79 |
$36,718 |
I/I |
5,408 |
22,709,077 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-05-17 |
4 |
AB |
$7.36 |
$45,641 |
I/I |
6,200 |
22,715,277 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-05-29 |
4 |
AB |
$7.55 |
$51,983 |
I/I |
6,882 |
22,759,592 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-06-04 |
4 |
AB |
$7.59 |
$56,911 |
I/I |
7,500 |
22,784,838 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-05-28 |
4 |
AB |
$7.68 |
$29,245 |
I/I |
3,807 |
22,752,710 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-05-24 |
4 |
AB |
$7.70 |
$29,233 |
I/I |
3,796 |
22,748,903 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-05-31 |
4 |
AB |
$7.70 |
$39,042 |
I/I |
5,071 |
22,771,914 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-06-03 |
4 |
AB |
$7.71 |
$41,815 |
I/I |
5,424 |
22,777,338 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-05-23 |
4 |
AB |
$7.76 |
$37,252 |
I/I |
4,802 |
22,745,107 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
10% Owner |
– – • |
2019-06-14 |
4 |
AB |
$7.91 |
$56,514 |
I/I |
7,144 |
22,841,809 |
0 |
- |
|
44 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
